Physician profile
Kelli Mccall
NPI 1023480274
$1,609.34
in general payments reported to CMS, 2019-2025
23 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $55.86 · 2022: $33.32 · 2023: $57.84 · 2024: $372 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.23 | 2024-2025 | |
| Pfizer INC. | $284.18 | 2025 | |
| Janssen Pharmaceuticals, INC | $108.61 | 2021-2023 | Xarelto |
| Lilly USA, LLC | $99.72 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $93.32 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $92.86 | 2024-2025 | Nuplazid |
| Ucb, INC. | $75.94 | 2024-2025 | Briviact, Rystiggo, Bimzelx |
| Biogen, INC. | $65.44 | 2025 | Vumerity, Tysabri, Leqembi |
| Takeda Pharmaceuticals U.S.A., INC. | $56.43 | 2025 | Hyqvia |
| Ge Healthcare | $46.97 | 2025 | |
| Mdd US Operations, LLC | $41.36 | 2024 | Gocovri |
| Lundbeck LLC | $39.20 | 2024-2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $34.23 | 2025 | Ponvory |
| Amgen INC. | $31.73 | 2024 | Enbrel, Otezla |
| Cycle Pharmaceuticals INC | $28.83 | 2025 | Tascenso Odt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27.66 | 2024 | |
| Solventum Corporation | $26.71 | 2025 | V.A.C. Granufoam, Promogran Prisma, Activ.A.C. |
| Axsome Therapeutics, INC. | $24.95 | 2025 | Symbravo |
| Gilead Sciences, INC. | $20.77 | 2023 | Veklury |
| Alexion Pharmaceuticals, INC. | $17.10 | 2024 | |
| Eisai INC. | $16.96 | 2025 | |
| Celgene Corporation | $15.06 | 2025 | Zeposia |
| Janssen Biotech, INC. | $13.08 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Mccall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.